Search

Your search keyword '"MESH : Immune Reconstitution Inflammatory Syndrome"' showing total 3 results
Start Over Descriptor "MESH : Immune Reconstitution Inflammatory Syndrome"
3 results on '"MESH : Immune Reconstitution Inflammatory Syndrome"'

1. Immune reconstitution inflammatory syndrome following allo-SCT in a patient with Dipodascus capitatus spondylodiscitis

Author

Claire Lacroix, S. Dimicoli, Cornet M, Fanny Lanternier, Zora Marjanovic, Lefebvre A, Bordonné C, Bernard Rio, Marie-Elisabeth Bougnoux, Olivier Lortholary, Simona Lapusan, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Thérapeutique Recombinante Expérimentale (TIMC-IMAG-TheREx), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Thérapeutique Recombinante Expérimentale ( TIMC-IMAG-THEREX ), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications [Grenoble] ( TIMC-IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Pasteur [Paris]

Subjects
Spondylodiscitis, MESH : Male, MESH : Discitis, MESH : Immune Reconstitution Inflammatory Syndrome, MESH : Stem Cell Transplantation, 03 medical and health sciences, 0302 clinical medicine, Immune reconstitution inflammatory syndrome, immune system diseases, hemic and lymphatic diseases, medicine, MESH : Middle Aged, 030212 general & internal medicine, Dipodascus capitatus, [ SDV.MP.MYC ] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, ComputingMilieux_MISCELLANEOUS, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, 0303 health sciences, Transplantation, MESH: Humans, MESH: Middle Aged, 030306 microbiology, business.industry, MESH : Humans, MESH: Dipodascus, Hematology, Allo sct, biochemical phenomena, metabolism, and nutrition, medicine.disease, MESH: Male, 3. Good health, MESH : Dipodascus, MESH: Discitis, surgical procedures, operative, MESH: Immune Reconstitution Inflammatory Syndrome, Immunology, MESH: Stem Cell Transplantation, business, human activities
Abstract

Immune reconstitution inflammatory syndrome following allo-SCT in a patient with Dipodascus capitatus spondylodiscitis

Published
2010

2. Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy eras

Author

Nicolas Dupin, Stéphane Bretagne, Jean-michel Molina, Willy Rozenbaum, Eric Dannaoui, Anne-Lise Bienvenu, Sophie Matheron, Cedric Arvieux, Stéphane Ranque, Service de réanimation médicale [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Mycologie moléculaire, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire ( CNRMA ), Institut Pasteur [Paris], Service d'informatique médicale et biostatistiques [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Service de Médecine Interne, GH Bichat-Claude Bernard, Paris, Centre de Référence Déficits Immunitaires Héréditaires ( CEREDIH ), Centre d'infectiologie Necker-Pasteur [CHU Necker], Thérapeutique Recombinante Expérimentale ( TIMC-IMAG-THEREX ), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications [Grenoble] ( TIMC-IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire (CNRMA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Pasteur [Paris], Thérapeutique Recombinante Expérimentale (TIMC-IMAG-TheREx), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), and Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP]

Subjects
Male, Antifungal Agents, MESH : Retrospective Studies, MESH : Immune Reconstitution Inflammatory Syndrome, MESH: Antiretroviral Therapy, Highly Active, 0302 clinical medicine, Immune Reconstitution Inflammatory Syndrome, immune system diseases, Antiretroviral Therapy, Highly Active, MESH: Histoplasmosis, MESH : Female, 030212 general & internal medicine, Young adult, MESH: Anti-HIV Agents, Histoplasmosis, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, [ SDV.MP.MYC ] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, 0303 health sciences, MESH : AIDS-Related Opportunistic Infections, MESH: Middle Aged, MESH : Prognosis, MESH: AIDS-Related Opportunistic Infections, Mortality rate, MESH : Acquired Immunodeficiency Syndrome, Highly active anti-retroviral therapy, virus diseases, Articles, Middle Aged, MESH : Adult, Prognosis, 3. Good health, Infectious Diseases, MESH: Young Adult, MESH: Immune Reconstitution Inflammatory Syndrome, Female, France, Adult, medicine.medical_specialty, Anti-HIV Agents, AIDS-Related Opportunistic Infections, MESH : Male, MESH : Antifungal Agents, MESH : Young Adult, MESH: Prognosis, 03 medical and health sciences, Young Adult, Immune reconstitution inflammatory syndrome, Acquired immunodeficiency syndrome (AIDS), MESH : Histoplasmosis, Virology, Internal medicine, medicine, Humans, MESH : Middle Aged, MESH : France, Retrospective Studies, MESH: Acquired Immunodeficiency Syndrome, Acquired Immunodeficiency Syndrome, MESH: Humans, 030306 microbiology, business.industry, MESH : Anti-HIV Agents, MESH : Humans, Retrospective cohort study, MESH: Retrospective Studies, MESH: Adult, medicine.disease, MESH: Antifungal Agents, MESH : Antiretroviral Therapy, Highly Active, MESH: Male, MESH: France, Immunology, Parasitology, business, MESH: Female
Abstract

International audience; Histoplasma capsulatum var. capsulatum infection is rare outside disease-endemic areas. Clinical presentation and outcome of acquired immunodeficiency syndrome-related histoplasmosis are unknown in non-endemic areas with wide access to highly active anti-retroviral therapy (HAART). Retrospective analysis of cases recorded at the French National Reference Center for Mycoses and Antifungals during two decades: pre-HAART (1985-1994) and HAART (1997-2006). Clinical features and outcome of all adults with proven acquired immunodeficiency syndrome-related histoplasmosis were compared between the two periods. One hundred four patients were included (40 during the pre-HAART era and 64 during the HAART era). Diagnosis was established a mean of 62 days after onset of symptoms. One-year overall mortality rates decreased from 53% (pre-HAART era) to 22% (HAART era). Diagnosis during the pre-HAART era and an older age were the only independent factors associated with death. Histoplasmosis is a rare invasive fungal infection outside disease-endemic areas. Its prognosis improved significantly during the HAART era.

Published
2011

3. Adjuvant corticosteroid therapy for chronic disseminated candidiasis

Author

Olivier Lortholary, Erianna Bellaton, Bertrand Dupont, Marc Lecuit, Faezeh Legrand, Pierre-Simon Rohrlich, Michel Huerre, Service d'hématologie et immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Microorganismes et Barrières de l'Hôte (Equipe avenir), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Histotechnologie et Pathologie, Institut Pasteur [Paris] (IP), Service d'hémato-onco-pédiatrie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Mycologie moléculaire, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Saas, Philippe, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 ( UPD7 ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -hopital Jean Minjoz, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Equipe avenir Microorganismes et Barrières de l'Hôte, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) ( HOTE GREFFON ), Université de Franche-Comté ( UFC ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), and Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS )

Subjects
Male, Abdominal pain, MESH : Retrospective Studies, MESH: Spleen, medicine.medical_treatment, MESH : Aged, MESH : Immune Reconstitution Inflammatory Syndrome, MESH: Length of Stay, MESH : Child, Adrenal Cortex Hormones, MESH: Child, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, Medicine, Child, 0303 health sciences, MESH: Middle Aged, Candidiasis, MESH : Chemotherapy, Adjuvant, 3. Good health, MESH : Length of Stay, C-Reactive Protein, Child, Preschool, MESH : Fever, Microbiology (medical), medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH : Abdominal Pain, Liver Abscess, MESH : Adrenal Cortex Hormones, MESH: Adrenal Cortex Hormones, 03 medical and health sciences, MESH : Adolescent, MESH: Fever, Humans, MESH : Middle Aged, Mycosis, Aged, Retrospective Studies, MESH: Adolescent, MESH: Humans, 030306 microbiology, MESH : Humans, MESH : Leukemia, MESH : Liver Abscess, MESH: Child, Preschool, MESH: Retrospective Studies, MESH: Adult, Length of Stay, medicine.disease, MESH: Antifungal Agents, MESH: Abdominal Pain, MESH: Fibrinogen, MESH: Female, Antifungal Agents, Time Factors, MESH : Fibrinogen, MESH : Child, Preschool, MESH : Candidiasis, Prednisone, Immune Reconstitution Inflammatory Syndrome, MESH : Female, MESH: Aged, Acute leukemia, Leukemia, MESH : Adult, Middle Aged, MESH: Candidiasis, Infectious Diseases, Chemotherapy, Adjuvant, MESH: Chemotherapy, Adjuvant, MESH: Immune Reconstitution Inflammatory Syndrome, Corticosteroid, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, medicine.symptom, MESH : Time Factors, medicine.drug, MESH : Spleen, Adult, Adolescent, Fever, medicine.drug_class, MESH : Male, MESH : Antifungal Agents, MESH: Liver Abscess, Immune reconstitution inflammatory syndrome, Internal medicine, MESH: Leukemia, MESH: C-Reactive Protein, 030304 developmental biology, Chemotherapy, business.industry, MESH: Time Factors, Fibrinogen, Retrospective cohort study, MESH : C-Reactive Protein, MESH: Male, Surgery, Abdominal Pain, business, Spleen
Abstract

International audience; BACKGROUND: Chronic disseminated candidiasis (CDC) is typically observed during neutrophil recovery in patients with acute leukemia and requires protracted antifungal therapy. OBJECTIVE: Our objective was to document the efficacy and tolerance of corticosteroid therapy (CST) in patients with symptomatic CDC, including those who experienced fever and abdominal pain despite ongoing antifungal therapy. METHODS: We performed a retrospective, multicenter study involving 10 pediatric and adult patients who experienced ongoing symptomatic CDC despite receipt of appropriate antifungal therapy for whom adjuvant oral CST was initiated. RESULTS: All cases of CDC were proven or probable, as determined on the basis of the European Organization for Research and Treatment of Cancer-Mycosis Study Group definition criteria, and occurred in patients with leukemia. CDC-attributable clinical symptoms resolved with CST, which was started a mean of 33.8 days after antifungal therapy had been initiated. Fever and abdominal pain disappeared a median of 4-5 days, and serum fibrinogen and C-reactive protein levels returned to normal values within 14-30 days. The median duration of hospitalization after CST initiation was 8.8 days. Hepatosplenic microabscesses decreased or disappeared within a mean period of 107 days (range, 30-210 days). No relapses of CDC were observed during a median duration of follow-up of 6.5 years (range, 4-9 years). CONCLUSIONS: In children and adults who experience persistently symptomatic CDC despite ongoing receipt of antifungal therapy, CST involving a prednisone equivalent at a dosage of > or =0.5 mg/kg per day for at least 3 weeks is associated with a prompt resolution of symptoms and of inflammatory response. These findings support the pathophysiological hypothesis that CDC belongs to the spectrum of fungus-related immune reconstitution inflammatory syndrome.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results